Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.

Augustin, H; Freibauer, C; Bayer, L; Lunglmayr, G; Tschurlovich, F; Kuber, W; Pummer, K

Augustin, H; Freibauer, C; Bayer, L; Lunglmayr, G; Tschurlovich, F; Kuber, W; Pummer, K.

Affiliation

Augustin H; Department of Urology, LKH Graz, Medical University of Graz, Graz, Austria. herbert.augustin@meduni-graz.at

Prostate Cancer Prostatic Dis ; 9(3): 279-83, 2006.

Article in En | MEDLINE | ID: mdl-16702984

Subject(s)

Androgen Antagonists/therapeutic use; Biomarkers, Tumor/analysis; Carcinoma/drug therapy; Prostatic Neoplasms/drug therapy; Aged; Aged, 80 and over; Anilides/administration & dosage; Anilides/therapeutic use; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma/diagnosis; Carcinoma/pathology; Cell Proliferation; Gene Expression Regulation, Neoplastic; Goserelin/administration & dosage; Goserelin/therapeutic use; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prognosis; Prostatic Neoplasms/diagnosis; Prostatic Neoplasms/pathology; Testosterone/blood; Tosyl Compounds; Withholding Treatment

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Carcinoma / Biomarkers, Tumor / Androgen Antagonists Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Prostate Cancer Prostatic Dis Journal subject: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Year: 2006 Type: Article Affiliation country: Austria

Search on Google

XML

PubMed Links